Citigroup Maintains Buy on Denali Therapeutics, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang maintains a Buy rating on Denali Therapeutics (NASDAQ:DNLI) and raises the price target from $26 to $32.
August 02, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst David Hoang maintains a Buy rating on Denali Therapeutics and raises the price target from $26 to $32.
The raised price target from $26 to $32 by a reputable analyst at Citigroup is a positive signal for investors, indicating confidence in Denali Therapeutics' future performance. This is likely to result in a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100